GLOBAL INSTITUTE FOR DISEASE ELIMINATION

INTERIM
Strategic Plan
2025–2030

Contents

Background	3
Value proposition	4
Achievements since 2020	7
Strategic approach	8
How we work	10
Where we work	13
Alignment with global health policies and priorities	15
Key Definitions	16

Acronyms

BMGF Bill and Melinda Gates Foundation Crown

CPC Prince Court, Abu Dhabi

DEEC Disease Elimination & Eradication Course

EID Eliminable Infectious Diseases

Falcon Awards Falcon Awards for Disease Elimination

GLIDE Global Institute for Disease Elimination

LF Lymphatic Filariasis

MENA Middle East and North Africa

NTDs **Neglected Tropical Diseases**

ODA Office of Development Affairs, Abu Dhabi

SDGs Sustainable Development Goals

UAE United Arab Emirates

WHO World Health Organization

Note: This strategy was developed and drafted in late 2024 and approved in early 2025 prior to significant shifts in the global health and development landscape. As a result, we have branded this an Interim Strategic Plan pending review in 2025 to ensure it responds appropriately to the development shifts and remains fit for purpose.

Background

In 2017, an idea took root—one that would build on decades of commitment to global health and push the boundaries of what was possible in disease elimination. Two years later, in 2019, that idea became reality with the official launch of the Global Institute for Disease Elimination (GLIDE), a pioneering institution based in Abu Dhabi. It was born from a partnership between His Highness Sheikh Mohamed bin Zayed Al Nahyan then Crown Prince of Abu Dhabi and now President of the United Arab Emirates and the Bill & Melinda Gates Foundation, and builds on the legacy and vision of the UAE's Founding Father Sheikh Zayed bin Sultan Al Nahyan. The origins of GLIDE can be traced back to a meeting between Sheikh Zayed and former US President Jimmy Carter more than 30 years ago that set in motion a deep and lasting engagement by the UAE in global health and development, fueling efforts to eradicate Guinea worm disease, combat polio, and eliminate malaria and neglected tropical diseases. These decades of commitment ultimately led to the creation of GLIDE as an independent entity, dedicated to advancing knowledge and accelerating progress toward sustainable infectious disease elimination. Today, as the world shifts and new challenges emerge, GLIDE carries this legacy forward, turning past commitments into present action. From its base in Abu Dhabi, it works closely with country partners and local actors to develop sustainable, locally led solutions while supporting operational research that expands the global understanding of disease elimination. By building on the past, GLIDE is shaping a future where infectious diseases are no longer a threat.

GLIDE was launched just before the onset of the COVID-19 pandemic, with most of its staff onboarded via Zoom and working remotely for a year before meeting in person. Shackled by the restrictions of the pandemic, GLIDE began operations by working in partnership with organizations in the infectious disease space, such as The Carter Center and Sightsavers. In these early days, because of the COVID constraints on travel and engagement, GLIDE used small grants and partnership agreements to help partners go further

and faster towards disease elimination This model has since evolved with most of GLIDE's resources (human and financial) used to further knowledge, capacity and awareness around disease elimination.

This new strategic plan for 2025-2030 defines GLIDE's evolved identity, sets out its mission, strategic pillars, and a toolkit of tactics that the institute draws upon to help achieve its vision of a world free of eliminable infectious diseases. It sees GLIDE firmly leaning into its role as a strategic advisor, convenor, facilitator, and accelerator for infectious disease elimination.



Value proposition

GLIDE is a strategic advisor, facilitator, convener, accelerator, and technical expert in infectious disease elimination and broader global health and development.

GLIDE's core mandate is infectious disease elimination. This is its key differentiator, as many global health organizations primarily focus on reducing the burden of disease. By prioritizing elimination, GLIDE sets forth an ambitious agenda to drive equitable health outcomes on a global scale.

GLIDE has a distinctive approach that

lies in its focus on knowledge generation and catalytic, collaborative investments, seeking opportunities for integrated action, enabling the organization to be both precise

and agile in its efforts. This allows GLIDE to swiftly identify and address critical gaps in disease elimination, thereby empowering partners to "move faster and further." As an independent and nimble entity, GLIDE can act as a catalyst, investing opportunistically and capitalizing on strategic

Jason Carter, Board Chair The Carter Center

Our work eliminating river

blindness in the Americas is a

perfect example of how GLIDE

can help accelerate them. ??

doesn't duplicate our efforts, but

opportunities. Further, the combination of GLIDE's unique positioning in Abu Dhabi and the broader Middle East with its strong focus on partnerships, allows it to serve as a bridge, linking regional priorities with global expertise and resources. As part of the **UAE's vision to expand its role in global** humanitarian and development, in its next five years of operation, GLIDE will further build on its role as a facilitator to connect **UAE** partners with the global health and development ecosystem and leverage capacities and strengths that exist within the UAE to identify opportunities for collaboration.

GLIDE's strength is rooted in local, regional, and global partnership. We work extensively with other stakeholders across the global health and disease

elimination spectrum. GLIDE collaborates with established entities in global health and development to envision pathways beyond disease control and invest in health and community systems that ensure the sustainability of elimination efforts, with a particular focus on integrated activities.

Why GLIDE?

GLIDE is a unique catalyst for disease elimination, accelerating expertise, innovation, and partnerships across the **MENA region and beyond**. With a sharp focus on translating knowledge into action, GLIDE empowers institutions and individuals to drive sustainable progress in global health.

As a specialized technical hub in the UAE and MENA, GLIDE advances infectious disease elimination and global health by advancing knowledge, advising decisionmakers, and supporting the next generation of scientists and public health leaders. Through strategic collaboration and thought leadership, GLIDE is shaping a future where disease elimination is not just a goal, but a lasting reality. This strategic focus enables GLIDE to leverage its expertise in epidemiology, health systems, and policy to address complex challenges in disease elimination. By applying lessons and best practices from ongoing elimination efforts, GLIDE shapes policies and practices that accelerate progress and close critical gaps in the elimination pathway.

GLIDE connects the MENA region with the world, cultivating expertise in disease elimination and advancing global health through collaboration, innovation, and strategic partnerships.

66


Being granted this funding was beyond exhilarating! Such grants have the ability to bring to light what is happening in the communities...and promotes cross-border collaboration. ??

Dr Therese Shema Nzayisenga, Director and Founder of the Climate JusticeFoundation, Zambia

Working collaboratively with partners, GLIDE develops innovative, evidence-based solutions tailored to the needs of vulnerable populations. This integrated approach not only enhances health outcomes but also strengthens health systems, ensuring sustainability and resilience in the face of emerging challenges.

In the context of a truly globalized approach to global health, GLIDE's location in

the Middle East provides a distinctive advantage. While many global health organizations are headquartered in the United States or Europe, GLIDE's base in the UAE positions it strategically close to Sub-Saharan Africa and South and Southeast Asia—regions where its focus diseases are most prevalent. This geographic proximity allows GLIDE to play a critical role in connecting regions that are central to disease elimination efforts.



GLIDE's strategic pillars—operational research, capacity strengthening, and advocacy —are designed to ensure that it acts as a catalyst for change, primarily through knowledge generation and advancement. Through advocacy, GLIDE raises awareness and drives political will toward elimination and wider global health goals, while its operational research efforts aim to generate critical insights and evidence that inform national and global health strategies. Capacity strengthening investments empower local health systems -through the support of the workforce and institutions—fostering sustainability and ownership of elimination initiatives in endemic regions. As we look to the next five years, we will also seek to explore how technology and digital innovation can be

applied to the field of infectious disease elimination, drawing upon the expertise of partners working in digital health and artificial intelligence, including those operating within the UAE ecosystem.

Furthermore, GLIDE's commitment to equitable health outcomes is reflected in its partnerships, which include both global and local stakeholders. GLIDE operates as an institute that works across sectors and leverages the UAE's global influence, which uniquely positions us to drive progress in disease elimination, serving as a provocateur, investor, and collaborative partner in the global health arena.



GLIDE symposium

Why elimination and eradication?

The paradox of disease elimination and eradication is well-known: as the goal of eliminating or eradicating a disease nears, resources, political will, and stakeholder interest often diminish. This phenomenon has left several diseases, many of which have afflicted humanity for centuries, persisting despite being classified as candidates for elimination or eradication. Historically, only two diseases have been eradicated—smallpox in humans and rinderpest in animals. While these efforts required substantial, sustained investments of time and resources, the benefits have been immeasurable. For instance, smallpox claimed an estimated 300-500 million lives in the 20th century alone, with children being disproportionately affected.

Today, many infectious diseases continue to devastate vulnerable populations. Of the 21 neglected tropical diseases (NTDs), which primarily impact underserved populations in tropical regions, two are considered eradicable, and 12 are targeted for elimination (interruption of transmission or elimination as public health problems -EPHP). However, these diseases suffer from both neglect and the elimination paradox, leading to underinvestment in the innovative technologies, localized strategies, and community-based approaches necessary to defeat them. Similarly, malaria is responsible for over 600,000 deaths annually, with 94% of the global malaria burden found on the African continent. Wild polio, with only 12 cases reported in 2023, has long been said to be the next disease to achieve the coveted status of eradication, but conflict, fatigue, cVDP2, and competing priorities threaten to stall progress. Collectively, these represent a critical missed opportunity to protect human

> health and to harness the broader societal benefits of scientific and technological advancements.

Over the past 120 years, advancements in knowledge and technology have contributed to an increase in global

life expectancy of 41 years—though this progress is not equally shared across all populations. Disease elimination is not merely an achievement in human ingenuity; it is a moral call that promotes equity, especially for the most disadvantaged communities, and would consign these ancient diseases to the history books. The elimination, and by extension, eradication, of diseases enables humanity to thrive, and the lessons learned from these efforts have far-reaching, multi-generational impacts on global health and development.

GLIDE targets its contribution and impact across the disease control-eliminationeradication spectrum, strategically positioning its efforts to address specific needs and opportunities within this continuum. Some aspects of GLIDE's work lean further toward the control end of the spectrum, particularly when the organization identifies a catalytic role in advancing elimination efforts or accelerating progress along the elimination pathway. Across our work, GLIDE aims to uncover and share insights into the appropriateness of elimination strategies for specific diseases, considering contextual factors such as resource availability, health system capacity, and emerging challenges. This nuanced approach enables GLIDE and its partners to focus on generating knowledge that is both context-sensitive and impactful to inform thoughtful and strategic decisions about disease elimination and other potential solutions to reduce the disease burden of eliminable infectious diseases.

Looking ahead, the future of global health and infectious disease elimination will be increasingly shaped by innovation, technology, and artificial intelligence (AI). GLIDE is committed to harnessing cuttingedge advancements in data analytics, predictive modeling, and digital health solutions to optimize disease surveillance, improve early detection, and enhance targeted intervention strategies. Al-driven insights can revolutionize how we map disease transmission, predict outbreaks, and tailor responses in real time, ultimately accelerating progress toward elimination. By integrating these technologies into global health strategies, GLIDE and its partners are pioneering a smarter, more adaptive approach to infectious disease elimination one that is data-driven, responsive, and capable of overcoming evolving health challenges with greater precision and efficiency.

GLIDE has established a strong reputation in the global health landscape and is considered an essential partner. ??

Waleed Al Muhairi, Board Chair, **GLIDE**

Achievements since 2020

Much of GLIDE's work to date has been cross-cutting across all three strategic pillars, employing an integrated approach. Some examples of success since 2020 include:



Introducing an annual, global award for disease elimination, the "Falcon Awards with **over \$1,000,000** awarded over the past 4 years to 19 awardees. These awards have an emphasis on early career researchers. (OR, CS, A1)



Built-up a leading course to enhance capacity for disease elimination; the "Disease Elimination & Eradication Course (DEEC)," with over 140 public health professionals from 30 countries successfully completing the course over the past 3 years. (CS)

GLIDE supported the establishment of an operational molecular surveillance laboratory for malaria, lymphatic filariasis, and other priority diseases in the Dominican Republic, in collaboration with the Ministry of Health (Centro de Prevención y Control de Enfermedades Transmitidas por Vectores y Zoonosis, CECOVEZ), the US CDC, and The Carter Center. (OR, CS)



Established as a major convener through a bi-annual symposium, with the inaugural symposium convening over 100 global partners representing over 30 countries in Abu Dhabi. (A)

NTDs (A, OR)

- Explored applications of innovative finance mechanisms as suitable complements to free drug donations
- Used economic analysis to better understand opportunities/trade-offs in disease elimination



RIVER BLINDNESS (CS, OR, A)

- Championed community involvement in shaping policies and practices for disease elimination, including mass drug administration and enhanced communication strategies to reach neglected populations.
- Supported WHO in the establishment of the Global Onchocerciasis Network for Elimination (GONE)

LYMPHATIC FILARIASIS/ NTDS (OR, A)

 Achieved regional guideline shifts at WHO to facilitate simultaneous drug administration in order to cover more diseases and to reduce costs



POLIO (OR, A)

Supported the introduction of advanced sequencing technology to quickly and thoroughly analyze polioviruspositive samples, enhancing surveillance and improving polio detection efforts in Pakistan.

MALARIA (A, OR)

- Helped establish the Malaria Elimination
 Consortium in Pakistan,
 together with Aga Khan
 University and the
 Department of Malaria
 Control, bringing together key stakeholders national and provincial level government, private sector, academic institutions, and NGOs.
- Supported revival of cross-border elimination plan between Indonesia and Timor-Leste

OR = Operational Research; CS = Capacity Strengthening; A = Advocacy

Strategic approach

GLIDE's strategy for 2025-2030 emphasizes a focus on achieving sustainable infectious disease elimination that also highlights

GLIDE's role as an institute, working to generate and disseminate knowledge for sustainable infectious disease elimination.



Vision and Mission

GLIDE envisions a world free of eliminable infectious diseases, and the institute aims to deliver on this vision through its mission of advancing knowledge and catalyzing action to accelerate progress towards sustainable disease elimination.

In strengthening the local ecosystem, this partnership helps affirm Abu Dhabi as a leading contributor to efforts to combat preventable disease, and an epicenter for global health progress, innovation and collaboration. ??

Nassar Al Mubarak, CEO, Reaching the Last Mile

Strategic Pillars

While GLIDE continues its focus on four priority diseases: lymphatic filariasis, onchocerciasis, malaria, and polio, this new strategy provides latitude for the Institute to undertake work along the elimination pathway for other infectious diseases, including exploring mechanisms and approaches that may put some diseases, such as dengue, on the path towards elimination.

The Injaz Fellowship will provide me with the expertise and leadership skills to be a pioneer in disease elimination in my country. ??

Lucrece Eteki, Epidemiologist, Cameroon

Principles

To deliver on its mission, GLIDE is committed to the following principles:

- Build on country ownership and local **solutions:** GLIDE is grounded in country realities and respect for the local context, capacities, knowledge, and leadership. It aims to build up and amplify lessons learned from the countries with which it engages. It takes a wide view to help countries share experiences, coordinate, and learn across contexts to accelerate progress towards elimination goals.
- Promote integrated and health system approaches: GLIDE believes that sustainable solutions require strong partnerships across public, private, international, and domestic actors focusing on cross-border, cross-sectoral, and cross-disease action. GLIDE will work through existing health systems rather than duplicating systems, creating silos, and taking resources from existing programs.
- Sustain progress: GLIDE seeks results that can be sustained for the long term, helping accelerate progress towards sustainable infectious disease elimination.
- Engage catalytically: GLIDE seeks to invest strategically, seizing opportunities and bridging gaps. It aims to move the field faster and further by pushing thinking and engendering action. GLIDE will guard against top-down development, and seeks to fill gaps, unlock barriers, and support coordinated efforts.

- Work in partnership: GLIDE actively collaborates across all its work to maximize impact and avoid duplication, helping partners go further, faster towards sustainable infectious disease elimination.
- Equity: Aligned with the 2030 Agenda for Sustainable Development, GLIDE believes in the principle of equity and leave no one behind
- Diversify and amplify voices: Building on the principle of equity, GLIDE seeks to diversify and amplify expert voices in infectious disease elimination, helping to bridge the gap between endemic country and global-level experts. To us diversity includes but is not limited to age. experience, gender, ethnicity, regional representation, sector, indigeneity, and all types of expertise.
- Enable Technology & Al Adoption: GLIDE is committed to harnessing technology and AI to accelerate disease Al researchers, and data experts to advance digital health solutions, predictive analytics, and Al-powered surveillance. We also advocate for

Out of Scope Statement

Outside of GLIDE's approach are areas and topics that do not align with our mission and strategic pillars, this includes but is not limited to non-communicable diseases. routine disease surveillance; routine program implementation and supplemental disease control activities; directly investing in innovative financing mechanisms and research and development; and long-term grantmaking.




Theory of Action

Since its inception in 2019, GLIDE has positioned itself to transformative change in global health, leveraging strategic partnerships and coalition-building to accelerate disease elimination.. GLIDE's theory of action illustrates the linkages

between its core activities, outputs, and outcomes, ultimately leading to its envisioned impact by 2030. The core activities represent the methods through which GLIDE operates across its strategic pillars and diseases of focus.







*Implementing units refers to sub-national units as defined by the national program, e.g., States, Provinces

How we work

At GLIDE, partnerships are the foundation of our approach, and we integrate our tactics into every collaboration. Exclusively anchored in Abu Dhabi, we extend our reach globally and locally through five core activities: partnerships, trainings, convenings, publications, and local outreach. Through partnerships with governments, academia, research institutes, policy entities, civil society, non-governmental organizations, product development partnerships, and private sector stakeholders we can achieve meaningful results by leveraging the collective strength of our global network. Across all our core activities, we seek to identify and support integrated approaches to disease elimination efforts, when there is a strong rationale for it. This is particularly crucial in an increasingly narrowed fiscal space for global health and development.

sharing initiatives, while also organizing and sponsoring key events to advance collaboration and innovation in disease elimination. Through these efforts, GLIDE contributes toward a robust global network dedicated to advancing and amplifying global knowledge to accelerate progress towards sustainable disease elimination.

Convene: As an Institute, GLIDE convenes experts from diverse fields to produce evidence-based knowledge products and provide a platform for connecting experts in the UAE with international global health partners. These resources aim to inform policy decisions and guide strategic actions to address disease elimination and global health challenges.

Publish: GLIDE supports the generation of robust evidence for disease elimination to i) demonstrate impact of strategies, ii) cultivate local champions to advocate for ongoing support, and iii) broaden the funding base by engaging diverse stakeholders and non-traditional funders. This approach is intended to create an enduring ecosystem of local and global advocates for longterm commitment and investment in disease elimination.

Local Outreach: As a global health institute based in the UAE, GLIDE seeks to increasingly become more active within its home ecosystem, building its reputation and visibility as a trusted, credible partner, convener, facilitator, and accelerator on global health-related matters. This will take the form of increased engagements within the UAE and at relevant regional health and development convenings, and includes collaborations with local universities, relevant ministries, and UAE-based entities,

to help further elevate the region and the

UAE as a burgeoning hub for global health.



Partner: GLIDE strategically supports operational research and advocacy, both through our Falcon Awards for Disease Elimination and through opportunistic partnerships. These projects, undertaken by exemplary researchers worldwide, help to deepen the understanding of complex health issues that affect all aspects of disease elimination. Our partners focus on real-world applications and on-the-ground challenges and generate valuable insights that inform policy and strategy for enhanced effectiveness of disease elimination interventions.



Train: To promote awareness and understanding of eliminable infectious diseases, GLIDE provides tailored training programs, including the Disease Elimination and Eradication Course, the Injaz Fellowship, and multi-topical Communities of Practice. These initiatives strengthen institutional capacity, foster expertise, and empower stakeholders to lead disease elimination efforts globally. In addition, GLIDE supports experts from endemic countries to participate in conferences, scientific meetings, and knowledge-

Advancing Disease Elimination through Strategic Initiatives

To date, GLIDE has successfully implemented several flagship initiatives, which will continue in this strategy, they include:

Falcon Awards for Disease Elimination

Since 2019, GLIDE has awarded over US\$1M to advance operational and formative research, as well as advocacy initiatives in disease elimination. Working with 18 partners across 15 countries, we have completed three iterations of our Falcon Awards for Disease Elimination. The Falcon Awards will continue to be a foundational initiative through which GLIDE helps strengthen capacity of early career researchers, add to the body of knowledge about infectious disease elimination, and advocate for sustainable change.


Disease elimination and eradication course (DEEC)

DEEC addresses a critical gap in global health by equipping participants with the skills to develop effective disease elimination strategies. From 2022-24 we implemented four cohorts and have trained over 130 public health professionals at sites in Abu Dhabi, Ghana and Rwanda, through collaboration with local universities and international non-governmental partners.

Injaz Fellowship

"Injaz" signifies accomplishment and embodies the spirit of our fellowship for leadership in disease elimination and global health. Our inaugural class of four mid-career fellows was launched in 2024—with an investment of \$50,000/fellow. We support their professional development through foundational trainings, project and research workshops, field studies, and participation in global health conferences and meetings.

Where we work



GLIDE's geographic focus is MENA and the world, which allows it to be demand responsive and nimble, identifying areas in which it can be catalytic and work in partnership with country and international actors to drive progress. Primarily, we identify countries and initiatives that align with our mission and mandate, and where we can facilitate progress along the elimination pathway.

Our criteria against which we test country and activity selection include the following: GLIDE's potential contribution, theory of action, value of investment, integration component, catalytic action, complementarity with existing efforts, and disease focus.

We have embraced our identity as an accelerator, convener, and knowledge hub. ??

Simon Bland, CEO, GLIDE

Alignment with global health policies and priorities

GLIDE's strategy aligns with the global health community's commitment to achieving ambitious disease elimination goals by 2030. Our focus on eliminating infectious diseases within our lifetime directly supports key global frameworks, including the Sustainable Development Goals (SDGs), the WHO Neglected Tropical Diseases (NTDs) Roadmap 2030 targets, the 2016-2030 Global Technical Strategy for Malaria, and the Immunization Agenda 2030. By setting our strategic timeline for 2025-2030, we position ourselves to meaningfully contribute to these shared global objectives.

Through targeted partnerships and catalytic investments in operational research, capacity strengthening, and advocacy, GLIDE's strategy aims to help inform and translate global policies into actionable approaches that address immediate health needs and drive long-term systemic improvements. Our approach seeks to

The institute's policy engagement spans three areas: policies which we can help drive, those which we can help shape, and ones we can develop. This approach allows us to remain agile in responding to shifting national and global priorities while aligning with WHO technical strategies for our focus diseases.

achieve specific disease elimination goals and strengthen health systems and policy environments to sustain these achievements.

Our work is closely linked to key SDG targets, particularly SDG 3 (Good Health and Wellbeing), which calls for ending the

epidemics of malaria, neglected tropical diseases, and other communicable diseases by 2030 (Target 3.3). We support the WHO NTD Roadmap's objectives, such as achieving the elimination of lymphatic filariasis and onchocerciasis as a public health problem in 58 and 12 countries, respectively. For malaria, we are aligned with the Global Technical Strategy's goal of reducing malaria incidence and

mortality rates by at least 90% by 2030 and eliminating malaria in at least 35 countries. Our efforts also contribute to the Immunization Agenda 2030, which aims to maintain high immunization coverage and eliminate diseases such as polio, reflecting our commitment to global polio eradication. The alignment is clear in our strategy as our impact goals reflect a contribution to a defined number of countries across all our focus diseases.


Furthermore, our integration-focused tactics enable us to contribute to additional SDG targets, such as SDG 6 (Clean Water and Sanitation) and SDG 4 (Quality Education). By aligning health interventions with water, sanitation, and hygiene (WASH) initiatives, we support Target 6.1, which aims for universal and equitable access to safe and affordable drinking water, and Target 6.2, which addresses access to adequate sanitation and hygiene. Moreover, recognizing that eliminable infectious diseases perpetuate the cycle of poverty by debilitating those affected and impeding human development, we also contribute to SDG 4. By improving health outcomes through disease elimination, we support educational attainment and promote equitable access to education, particularly Targets 4.1 and 4.5, which focus on quality education for all and eliminating gender disparities.

AS GLIDE ENTERS ITS NEXT FIVE YEARS OF OPERATION, it does so with a clear focus and specific goals, leaning

into its identity as an institute focused on accelerating sustainable infectious disease elimination. The institute's clear theory of action will drive all its engagements and partnerships, helping to drive and sustain momentum towards elimination and eradication. We invite you to join us on the journey to elimination and help us to consign these ancient diseases to the history books.

Key Definitions

- Control: Reduction of disease incidence, prevalence, morbidity and/or mortality to a locally acceptable level as a result of deliberate efforts; continued intervention measures are required to maintain the reduction. Control may or may not be related to global targets set by WHO.
- Elimination as a public health problem (EPHP): A term related to both infection and disease that is defined by the achievement of measurable global targets set by WHO in relation to a specific disease. When reached, continued actions are required to maintain the targets and/or to advance the interruption of transmission. The process of documenting elimination as a public health problem is called validation.
- Elimination of transmission (also referred to as interruption of transmission): (also referred to as interruption of transmission): Reduction to zero of the incidence of infection caused by a specific pathogen in a defined geographic area, with minimal risk of reintroduction, as a result of deliberate efforts; continued actions to prevent reestablishment of transmission may be required. The process of documenting elimination of transmission is called verification.
- Eradication: Permanent reduction to zero of a specific pathogen, as a result of deliberate efforts, with no more risk of reintroduction. The process of documenting eradication is called certification.
- Extinction: Eradication of a specific pathogen so that it no longer exists in nature or the laboratory, which may occur with or without deliberate efforts.



www.glideae.org • info@glideae.org

The Global Institute for Disease Elimination (GLIDE) is a global health institute based in Abu Dhabi that envisions a world free of eliminable infectious diseases by 2030 and beyond. GLIDE works across three strategic pillars: operational research, capacity strengthening, and advocacy to advance its mission with a current disease focus of malaria, polio, lymphatic filariasis, and river blindness. GLIDE seeks to promote integrated solutions to help partners

go further and faster to achieve sustainable disease elimination.

ABOUT GLIDE